EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials

Michaël J B van Baar, Petter Bjornstad, Daan J Touw, Jaap A Joles iD, Merle M Krebber, David Z I Cherney, Daniël H van Raalte, Marcel H A Muskiet

Nephrology Dialysis Transplantation · 2026

DOI: 10.1093/ndt/gfag025 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Michaël J B van Baar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Center, Department of Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis Glomerular hyperfiltration is common in type 2 diabetes (T2D) and may reflect reduced nephron number and/or perturbed intrarenal hemodynamics. Renal functional reserve (RFR), the capacity to increase GFR with physiological stimuli (e.g. a meal), may help reveal single-nephron hyperfiltration in patients with preserved baseline whole-kidney GFR. We hypothesized that reduced postprandial RFR predicts the acute hemodynamic GFR-response in T2D to the sodium-glucose co-transporter-2 inhibitor empagliflozin, but not to the dipeptidyl-peptidase-4 inhibitor linagliptin or a sulfonylurea.

Methods

This analysis pooled data from two 8-week randomized, double-blind, parallel-group mechanistic trials, encompassing 71 T2D patients with preserved whole-kidney GFR (mean ± SD age 65 ± 7 yrs, BMI 30.4 ± 3.9 kg/m2, HbA1c 7.8 ± 1.0% [61.6 ± 11.0 mmol/mol], GFR 86.5 ± 17.6 mL/min/1.73m2). Patients received empagliflozin (10 mg; N = 20), linagliptin (5 mg; N = 27) or sulfonylurea (glimepiride 1 mg, or gliclazide 30 mg; N = 24), in addition to metformin. Measured (m)GFR and effective renal plasma flow (ERPF) were determined by inulin/iohexol and PAH-clearance, respectively, based on timed urine-sampling in fasting and post-protein-rich meal conditions. Intrarenal-hemodynamics were calculated using Gomez-equations; fractional sodium-excretion (FENa) and systemic hemodynamics were evaluated.

Results

The meal increased mGFR (+7.3 ± 1.7 mL/min/1.73m2; P < 0.001) and ERPF (+44.3 ± 14.9 mL/min/1.73m2; P = 0.005), with concomitant decrease in renal vascular resistance (RVR; −0.02 ± 0.01 mmHg/L/min; P < 0.001), driven by reduced afferent arteriolar resistance (−1068 ± 241dyne/sec/cm−5; P < 0.001) and lower FENa (−0.21 ± 0.05; P < 0.001). Postprandial mGFR-changes did not correlate with baseline mGFR, but did correlate with postprandial RVR-change (r − 0.57; P < 0.001). After 8 weeks, mGFR tended to decrease with sulfonylurea (P = 0.054) and decreased with empagliflozin (−9.1 ± 3.2 mL/min/1.73m2; P = 0.016), but not with linagliptin. Baseline meal-induced mGFR-changes correlated with 8-week treatment-induced mGFR-changes with empagliflozin (r:0.88; P < 0.001), but not with linagliptin or sulfonylurea.

Conclusion

Baseline postprandial-RFR predicts GFR-dipping with empagliflozin after 8-weeks, but not with GFR-changes following linagliptin or sulfonylurea. As initial GFR-dipping is associated with long-term kidney benefit, RFR warrants evaluation as a potential additional tool to personalize SGLT2i-therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsDiabetes Mellitus, Type 2Glomerular Filtration RateGlucosidesKidneyAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodFollow-Up StudiesHypoglycemic AgentsKidney Function TestsLinagliptinPrognosisRandomized Controlled Trials as TopicSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

DPP-4 inhibitionSGLT2-inhibitionglomerular hyperfiltrationrenal functional reservetype 2 diabetes

Substanzen

Benzhydryl CompoundsempagliflozinGlucosidesHypoglycemic AgentsLinagliptinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Diabetes Center, Department of Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
  • Division of Endocrinology, Department of Pediatrics, and Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, UMCG, Groningen, The Netherlands.
  • Department of Nephrology and Hypertension, UMC, Utrecht, The Netherlands.
  • Department of Medicine, Division of Nephrology, University Health Network, Toronto General Hospital Research Institute, Toronto, Ontario, Canada.
  • Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Jaap A Joles

Förderung

  • Boehringer Ingelheim

Zitieren

APA

van Baar, M. J. B., Bjornstad, P., Touw, D. J., Joles, J. A., Krebber, M. M., Cherney, D. Z. I., van Raalte, D. H., & Muskiet, M. H. A. (2026). Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag025

Vancouver

van Baar MJB, Bjornstad P, Touw DJ, Joles JA, Krebber MM, Cherney DZI, et al. Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag025

BibTeX
@article{vanBaar2026,
  author = {van Baar, Michaël J B and Bjornstad, Petter and Touw, Daan J and Joles, Jaap A and Krebber, Merle M and Cherney, David Z I and van Raalte, Daniël H and Muskiet, Marcel H A},
  title = {Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag025}
}
Kostenlos starten →